<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0211-6995</journal-id>
<journal-title><![CDATA[Nefrología (Madrid)]]></journal-title>
<abbrev-journal-title><![CDATA[Nefrología (Madr.)]]></abbrev-journal-title>
<issn>0211-6995</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Nefrología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0211-69952017000500501</article-id>
<article-id pub-id-type="doi">10.1016/j.nefro.2017.02.006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Calcifilaxis: más allá de CKD-MBD]]></article-title>
<article-title xml:lang="en"><![CDATA[Calciphylaxis: Beyond CKD-MBD]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Polanco]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mérida]]></surname>
<given-names><![CDATA[Eva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Praga]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario 12 de Octubre Servicio de Nefrología ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>37</volume>
<numero>5</numero>
<fpage>501</fpage>
<lpage>507</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0211-69952017000500501&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0211-69952017000500501&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0211-69952017000500501&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La arteriolopatía urémica calcificante (CUA), también llamada calcifilaxis, es un trastorno vascular poco frecuente pero potencialmente mortal que afecta casi exclusivamente a pacientes con insuficiencia renal crónica. El objetivo de este estudio fue analizar los diferentes factores de riesgo para el desarrollo de CUA y su posterior evolución según la terapia recibida.  Material y métodos: Estudio retrospectivo que recoge aquellos pacientes con diagnóstico de CUA desde diciembre de 1999 hasta diciembre de 2015. Se analizaron diferentes factores de riesgo, evolución y diferentes opciones terapéuticas.  Resultados: Se incluyeron 28 pacientes (53,6% mujeres) con una edad media de 67,2 ± 11,8 años (38-88). En el momento del diagnóstico, el 53,6% estaba en hemodiálisis, un 25% eran pacientes con un trasplante renal y el 21,4% presentaba función renal normal. En los pacientes trasplantados, el consumo de esteroides (100%; p = 0,001) fue el principal factor de riesgo. La resolución de lesiones cutáneas se produjo en el 60,7% (especialmente en los que recibieron tratamiento multitarget). La supervivencia de los pacientes a los 12meses fue de 29, 57 y 100% en los pacientes trasplantados, hemodiálisis y con función renal normal respectivamente (log-rank 6,88; p = 0,032). La presencia de insuficiencia renal crónica (p = 0,03) e hipoalbuminemia (p = 0,02) fueron los principales factores de riesgo de mortalidad CUA.  Conclusión: Aunque la incidencia de la CUA sigue siendo baja, su mortalidad es muy elevada, por lo que debe prestarse especial atención a la presentación de la CUA en los trasplantados renales y en las formas «no renales». Los anticoagulantes orales y los esteroides aparecen como principales factores de riesgo. La CUA es un reto: necesitamos un registro de nuestros pacientes y establecer una terapia estándar.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Calcific uraemic arteriolopathy (CUA), also called calciphylaxis, is a rare but potentially fatal vascular disorder that almost exclusively affects patients with chronic renal failure. The objective of this study was to analyse various risk factors for developing CUA and its subsequent clinical course according to the treatment received.  Materials and methods: A retrospective study that included patients diagnosed with CUA from December 1999 to December 2015. Various risk factors, clinical course and treatment options were analysed.  Results: A total of 28 patients (53.6% females) with a mean age of 67.2 ± 11.8 (38-88) years were included. At the time of diagnosis, 53.6% were on haemodialysis, 25% were kidney transplant patients and 21.4% had normal renal function. The use of steroids (100%, P = .001) was the main risk factor in renal transplant patients. Skin lesions resolved in 60.7% (especially in those receiving multitargeted therapy). Patient survival at 12 months was 29% in transplant patients, 57% in haemodialysis patients and 100% in normal renal function patients (log-rank 6.88, P = .032). Chronic renal failure (P = .03) and hypoalbuminaemia (P = .02) were the main risk factor for CUA mortality.  Conclusions: Although the incidence of CUA remains low, CUA mortality is very high, Special attention to its occurrence in kidney transplant patients and «non-renal» CUA forms is required. Oral anticoagulants and steroids appear to be the main risk factors, CUA is a challenge; a registry of patients and determining standard therapy are required.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Calcifilaxis]]></kwd>
<kwd lng="es"><![CDATA[Insuficiencia renal crónica]]></kwd>
<kwd lng="es"><![CDATA[Mortalidad]]></kwd>
<kwd lng="es"><![CDATA[Formas no renales]]></kwd>
<kwd lng="es"><![CDATA[Anticoagulantes orales]]></kwd>
<kwd lng="en"><![CDATA[Calciphylaxis]]></kwd>
<kwd lng="en"><![CDATA[Chronic renal failure]]></kwd>
<kwd lng="en"><![CDATA[Mortality]]></kwd>
<kwd lng="en"><![CDATA[Non-renal forms]]></kwd>
<kwd lng="en"><![CDATA[Oral anticoagulants]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vascular calcification: The killer of patients with chronic kidney disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mizobuchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Towler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Slatopolsky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2009</year>
<volume>20</volume>
<page-range>1453-64</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calciphylaxis: Natural history, risk factor analysis and outcome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weening]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Sewell]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Pittelkow]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2007</year>
<volume>56</volume>
<page-range>569-79</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[La arteriopatía calcificante urémica (calcifilaxis) en el contexto del síndrome metabólico y la diabetes mellitus. Perspectiva actual]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>20-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors and mortality associated with calciphylaxis in end-stage renal disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazhar]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gillen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stivelman]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>2001</year>
<volume>60</volume>
<page-range>324-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcific uremic arteriolopathy: An update]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Nephrol Hypertens]]></source>
<year>2008</year>
<volume>17</volume>
<page-range>629-34</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcific uremic arteriolopathy in association with low turnover uremic bone disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mawad]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Sawaya]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Sarin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malluche]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Nephrol]]></source>
<year>1999</year>
<volume>52</volume>
<page-range>160-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Control of serum phosphorus: Implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Nephrol Hypertens]]></source>
<year>2001</year>
<volume>10</volume>
<page-range>741-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcifilaxis: complicación grave del síndrome cardio-metabólico en pacientes con enfermedad renal crónica terminal (ERCT)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdalles Guzmán]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Cueva]]></surname>
<given-names><![CDATA[P de la]]></given-names>
</name>
<name>
<surname><![CDATA[García de Vinuesa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goicoechea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mosse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López Gómez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>32-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A case-control study of calciphylaxis in Japanese end stage renal disease patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayasi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Takamatsu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kanno]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2012</year>
<volume>27</volume>
<page-range>1580-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moe]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Reslerova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ketteler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O'Neill]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Koczman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>2005</year>
<volume>67</volume>
<page-range>2295-304</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fetuin A protects against atherosclerotic calcification in CKD]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Westenfeld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Krüger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Haarmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schurgers]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reutelingsperger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2009</year>
<volume>20</volume>
<page-range>1264-2174</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evolution of treatment strategies for calciphylaxis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Nephrol]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>460-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multi-intervention management of calciphylaxis: A report of 7 cases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Farah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Werb]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kiaii]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>988-91</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): A case series]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Capuano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cozzolino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Napolitano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mosella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Kidney J]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>108-12</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcific uremic arteriolopathy revisited]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jovanovich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chonchol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calciphylaxis from nonuremic causes: A systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nigwekar]]></surname>
<given-names><![CDATA[SU]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sterns]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Hix]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2008</year>
<volume>3</volume>
<page-range>1139-43</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calciphylaxis: Controversies in pathogenesis, diagnosis and treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med Sci]]></source>
<year>2016</year>
<volume>351</volume>
<page-range>217-27</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calciphylaxis in the current era: Emerging 'ironic' features?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chan Yan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2011</year>
<volume>26</volume>
<page-range>191-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcific uremic arteriolopathy: A call for action]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandenburg]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Cozzolino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzaferro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Semin Nephrol]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>641-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A nationally representative study of calcific uremic arteriolopathy risk factors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nigwekar]]></surname>
<given-names><![CDATA[SU]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wenger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hymes]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Maddux]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Thadhani]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Progression of vascular calcification in uraemic patients: Can it be stopped?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drüeke]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Rostand]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2002</year>
<volume>17</volume>
<page-range>1365-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcific uraemic arteriolopathy (calciphylaxis): A data from a large nationwide registry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandenburg]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Kraman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rothe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kaesler]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Korbiel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Specht]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: Case report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Trasplant]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>1260-2</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tratamiento de calcifilaxis distal con terapia asociada de sevelamer y bifosfonatos]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>92-3</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Severe nonuremic calciphylaxis due to hyperphosphatemia resolving with multimodality treatment including phosphate binders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanat]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Negoianu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenbach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA Dermatology]]></source>
<year>2014</year>
<volume>150</volume>
<page-range>671-3</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multimodal treatment of calciphylaxis with sodium thiosulfate, cinacalcet and sevelamer including long term data]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salmhofer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Franzen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hitzl]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Koller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kreymann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fend]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2013</year>
<volume>37</volume>
<page-range>346-59</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proximal calciphylaxis treated with calcimimetico "cinacalcet"]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohammed]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Sekar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bubtana]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mitra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2008</year>
<volume>23</volume>
<page-range>387-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Floege]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Floege]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chertow]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Parfrey]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>800-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Derendorf]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2011</year>
<volume>6</volume>
<page-range>1155-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tratamiento eficaz de la arteriolopatía urémica calcificantes con bifosfonatos]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torregrosa]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Barros]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Blasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cases]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2012</year>
<volume>32</volume>
<page-range>329-34</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monney]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[QV]]></given-names>
</name>
<name>
<surname><![CDATA[Perroud]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Descombes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Trasplant]]></source>
<year>2004</year>
<volume>19</volume>
<page-range>2130-2</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Westenfeld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krueger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schlieper]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cranenburg]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Magdeleyns]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2012</year>
<volume>59</volume>
<page-range>186-95</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hyperbaric oxygen in the treatment of calciphylaxis: A case series]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podymow]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wherrett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2001</year>
<volume>16</volume>
<page-range>2176-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
